Anti-Coagulants - Bulgaria

Bulgaria

The revenue in the Anti-Coagulants market in Bulgaria is projected to reach US$15.77m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 7.43%, resulting in a market volume of US$22.57m by 2029.
In global comparison, United States is expected to generate the highest revenue of US$16,740.00m in 2024.
Bulgaria is experiencing an increasing demand for novel oral anticoagulants as a preferred choice for the treatment of cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Bulgaria has been experiencing steady growth in recent years.

Customer preferences: Bulgarian customers have been showing a growing preference for Anti-Coagulants medication due to the increasing incidence of cardiovascular diseases. Additionally, the aging population has also contributed to the growth of the Anti-Coagulants market as the elderly are more susceptible to heart-related illnesses.

Trends in the market: The Anti-Coagulants market in Bulgaria is dominated by the oral anticoagulant segment due to the convenience and ease of use of these medications. There has also been a growing trend towards the use of direct oral anticoagulants (DOACs) as they offer a lower risk of bleeding compared to traditional anticoagulants. The market has also seen an increase in the use of combination therapies, where different types of anti-coagulants are used together to manage complex cases.

Local special circumstances: Bulgaria has a high incidence of cardiovascular diseases, which has contributed to the growth of the Anti-Coagulants market. Additionally, the country has a well-developed healthcare system, which has made it easier for patients to access these medications. However, there are still challenges in terms of affordability, as some patients may not be able to afford the high cost of these medications.

Underlying macroeconomic factors: The Bulgarian economy has been growing steadily in recent years, which has contributed to the growth of the Anti-Coagulants market. Additionally, the government has been investing in healthcare infrastructure, which has made it easier for patients to access these medications. However, there are still challenges in terms of the affordability of these medications, which may limit their growth potential in the future.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.